Indivior

Last updated

Indivior
Company typePublic company
Industry Pharmaceutics
Founded1994
Headquarters Richmond, Virginia
Key people
Graham Hetherington, Chairman
Mark Crossley, CEO
Products Subutex/Subuxone/Sublocade
RevenueIncrease2.svg $1,093 million (2022) [1]
Increase2.svg $(4) million (2022) [1]
Increase2.svg $2 million (2023) [1]
Website www.indivior.com/

Indivior is a specialty pharmaceuticals business. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, the company has been fined for false marketing claims about the safety of its drug, Suboxone. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. It is also listed on the NASDAQ Global Select Market.

Contents

History

The company was established as the Buprenorphine division of Reckitt Benckiser in 1994. [2] In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior. [3] By February 2015, the company was capitalised at £2.3 billion (US$3.1 billion) on the London Stock Exchange. [4]

In 2019, Indivior was indicted over claims that it had made false marketing claims about the safety of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with the Justice Department to pay $1.4 billion to resolve a U.S. Federal investigation into sales and marketing of opioid addiction treatment. [5] [6] [7]

In July 2020, Indivior Solutions, Indivior Inc., and Indivior PLC agreed to pay $600 million to resolve liability related to false marketing of Suboxone to MassHealth for use by patients with children under the age of six years old. Additionally, Indivior Solutions Inc pleaded guilty to one-count of felony information. [8]

In November 2022, it was announced Indivior had acquired the Santa Monica-headquartered, NASDAQ-listed biopharmaceutical company, Opiant. [9]

In July 2023 Indivior paid $20.4 million to C4X Discovery for the full rights to the orexin-1 receptor antagonist being developed for substance use disorder. Indivior had already made an upfront payment of $10 million in 2018 and pledged milestone payments of up to $284 million. Under the new agreement C4X Discovery waived any rights to further payment. [10]

Operations

The company's main products are Sublocade, Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction. [2] Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world. [11]

Related Research Articles

<span class="mw-page-title-main">Buprenorphine</span> Opioid used to treat pain & opioid use disorder

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection, as a skin patch (transdermal), or as an implant. For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

<span class="mw-page-title-main">Reckitt</span> British multinational consumer goods company

Reckitt Benckiser Group PLC, trading as Reckitt, is a British multinational consumer goods company headquartered in Slough, England. It is a producer of health, hygiene and nutrition products. The company was formed in March 1999 by the merger of British company Reckitt & Colman plc and Dutch company Benckiser N.V.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Purdue Pharma</span> American pharmaceutical company (1892–2019 bankruptcy)

Purdue Pharma L.P., formerly the Purdue Frederick Company (1892–2019), was an American privately held pharmaceutical company founded by John Purdue Gray. It was sold to Arthur, Mortimer, and Raymond Sackler in 1952, and then owned principally by the Sackler family and their descendants.

<span class="mw-page-title-main">Mallinckrodt</span> Irish domiciled pharmaceutical

Mallinckrodt Pharmaceuticals is an American-Irish domiciled manufacturer of specialty pharmaceuticals, generic drugs and imaging agents. In 2017, it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar was Medicaid's most expensive drug.

Mead Johnson & Company, LLC is an American company that is a leading manufacturer of infant formula, both domestically and globally, with its flagship product Enfamil. It operates as an independent subsidiary of Reckitt.

The ethics involved within pharmaceutical sales is built from the organizational ethics, which is a matter of system compliance, accountability and culture. Organizational ethics are used when developing the marketing and sales strategy to both the public and the healthcare profession of the strategy. Organizational ethics are best demonstrated through acts of fairness, compassion, integrity, honor, and responsibility.

<span class="mw-page-title-main">ISTA Pharmaceuticals</span> US-based pharmaceutical company

ISTA Pharmaceuticals, Inc, was a US-based pharmaceutical company that specialized in ophthalmic pharmaceutical products and discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. ISTA was acquired by Bausch & Lomb, an eye care company, on March 26, 2012. Under the deal, Bausch & Lomb have agreed to pay $9.10 per share for ISTA, bringing the total value of the acquisition to $500 million. In 2012, Valeant Pharmaceuticals withdrew its $360 million offer.

Nicandro Durante is a Brazilian businessman who served as the chief executive officer (CEO) of British American Tobacco (BAT), the world's largest tobacco company by sales, from 2011 to 2019. In September 2022 he was appointed as temporary CEO of Reckitt Benckiser.

Rakesh Kapoor is an Indian businessman. He was, until September 2019, chief executive (CEO) of Reckitt plc, a UK FTSE-listed multinational consumer goods company, a major producer of health, hygiene and home products.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

<span class="mw-page-title-main">Buprenorphine/naloxone</span> Opioid treatment

Buprenorphine/naloxone, sold under the brand name Suboxone among others, is a fixed-dose combination medication that includes buprenorphine and naloxone. It is used to treat opioid use disorder, and reduces the mortality of opioid use disorder by 50%. It relieves cravings to use and withdrawal symptoms. Buprenorphine/­naloxone is available for use in two different forms, under the tongue or in the cheek.

<span class="mw-page-title-main">Vanish (stain remover)</span> Stain removing brand from Reckitt

Vanish is a brand of stain removing products, owned by the product manufacturer Reckitt, and sold in Australia, India, Indonesia, Russia, South Africa, Latin America and parts of Europe.

Founded in 1990, Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve peaks of pain in cancer patients.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

<span class="mw-page-title-main">Opioid epidemic in the United States</span> Ongoing overuse of opioid medication in the US

There is an ongoing opioid epidemic in the United States, originating out of both medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s, according to the Centers for Disease Control and Prevention (CDC), when opioids were increasingly prescribed for pain management, resulting in a rise in overall opioid use throughout subsequent years.

Massachusetts v. Purdue is a lawsuit filed on August 14, 2018, suing the Stamford, Connecticut-based company Purdue Pharma LP, which created and manufactures OxyContin, "one of the most widely used and prescribed opioid drugs on the market", and Purdue's owners, the Sacklers accusing them of "widespread fraud and deception in the marketing of opioids, and contributing to the opioid crisis, the nationwide epidemic that has killed thousands." Purdue denied the allegations.

References

  1. 1 2 3 "Annual Results 2023" (PDF). Indivior. Retrieved 22 February 2023.
  2. 1 2 "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. "Is Indivior PLC The Perfect Partner For AstraZeneca plc in Your Portfolio?" . Retrieved 22 March 2015.
  5. "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. 11 July 2019. ISSN   0362-4331 . Retrieved 11 July 2019.
  6. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Wall Street Report. Retrieved 11 July 2019.
  7. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. 11 July 2019. Retrieved 11 July 2019.
  8. "Indivior Solutions Pleads Guilty to Felony Charge as Part of DOJ's Largest Opioid Resolution". uspsoig.gov. United States Postal Service Office of Inspector General. 24 July 2020. Retrieved 7 September 2020. Indivior Solutions today pleaded guilty to a one-count felony information and, together with its parent companies Indivior Inc. and Indivior PLC, agreed to pay a total of $600 million to resolve criminal and civil liability associated with the marketing of the opioid-addiction-treatment drug Suboxone. All other charges against Indivior were dismissed. Together with a $1.4 billion resolution with Indivior's former parent, Reckitt Benckiser Group PLC (RB Group), announced in 2019, and a plea agreement with Indivior plc's former CEO, Shaun Thaxter, announced last month, the total resolution relating to the marketing of Suboxone is more than $2 billion.
  9. Media, Insider. "Indivior to acquire US biopharmaceutical company". Insider Media Ltd. Retrieved 15 November 2022.
  10. Waldron, James (1 August 2023). "C4X sells full rights for substance use disorder drug to Indivior as part of refocus". Fierce Biotech. Retrieved 28 September 2023.
  11. "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.